Recipharm has announced that its proprietary molecule Erdosteine has been officially recognised by the GOLD (Global Initiative for Chronic Obstructive Lung disease) Scientific Committee as one of the commonly used maintenance medications in COPD (Chronic Obstructive Pulmonary Disease)
Erdosteine, which was discovered and developed in Italy by Recipharm’s facility in Paderno Dugnano, has been listed in the 2019 GOLD report.
Since its introduction in 2001, the GOLD report has become a leading worldwide reference for all healthcare professionals and health authorities for the effective diagnosis, management and prevention of COPD.
Products containing Erdosteine from Recipharm are now marketed in more than 40 countries across the world and is available in four different dosage forms including a capsule, sachet, dispersible tablet and suspension.
Recipharm supplies Erdosteine as both API (active pharmaceutical ingredient) and as finished dose form to its customers.
Pierfrancesco Manzo, Sales & Business Development Director for Erdosteine, commented: “This is an important recognition of the scientific value of our molecule and it has been achieved thanks to the outcomes of the recent clinical studies, which proved Erdosteine to be effective in the treatment of COPD patients. We are confident that Erdosteine is going to play an increasing role in the treatment of this pathology.”
The recognition in the GOLD report follows extensive research as part of the RESTORE study published in 2017, which saw 467 patients in ten countries undergo 12 months of treatment with positive results that support its clinical effectiveness.
Erdosteine’s pharmacological profile is characterised by unique multifactorial activity: mucomodulatory, antibacterial, anti-inflammatory and antioxidant.
The chemical synthesis of the active pharmaceutical ingredient (API) and the manufacture of capsules and dispersible tablets is performed in Recipharm’s Paderno Dugnano facility, located just outside of Milan.